Generic placeholder image

Current Stem Cell Research & Therapy

Editor-in-Chief

ISSN (Print): 1574-888X
ISSN (Online): 2212-3946

Systematic Review Article

A Systematic Review and Meta-Analysis: Safety and Efficacy of Mesenchymal Stem Cells Therapy for Heart Failure

Author(s): Tiantian Shen, Lin Xia, Wenliang Dong, Jiaxue Wang, Feng Su, Suping Niu, Qian Wang and Yi Fang*

Volume 16, Issue 3, 2021

Published on: 20 August, 2020

Page: [354 - 365] Pages: 12

DOI: 10.2174/1574888X15999200820171432

Price: $65

Abstract

Background: Preclinical and clinical evidence suggests that mesenchymal stem cells (MSCs) may be beneficial in treating Heart Failure (HF). However, the effects of stem cell therapy in patients with heart failure is an ongoing debate and the safety and efficacy of MSCs therapy are not well-known. We conducted a systematic review of clinical trials that evaluated the safety and efficacy of MSCs for HF. This study aimed to assess the safety and efficacy of MSCs therapy compared to the placebo in heart failure patients.

Methods: We searched PubMed, Embase, Cochrane library systematically, with no language restrictions. Randomized Controlled Trials (RCTs) assessing the influence of MSCs treatment function controlled with placebo in heart failure were included in this analysis. We included RCTs with data on safety and efficacy in patients with heart failure after mesenchymal stem cell transplantation. Two investigators independently searched the articles, extracted data, and assessed the quality of the included studies. Pooled data was performed using the fixed-effect model or random-effect model by the use of Review Manager 5.3. The Cochrane risk of bias tool was used to assess the bias of included studies. The primary outcome was safely assessed by death and rehospitalization and the secondary outcome was efficacy, which was assessed by six-minute walk distance and Left Ventricular Ejection Fraction (LVEF), Left Ventricular End-systolic Volume (LVESV), Left Ventricular End-diastolic Volume (LVEDV) and Brain Natriuretic Peptide (BNP).

Results: A total of twelve studies were included, involving 823 patients who underwent MSCs or placebo treatment. The overall rate of death showed a trend of reduction of 27% (RR [CI]=0.73 [0.49, 1.09], p=0.12) in the MSCs treatment group. The incidence of rehospitalization was reduced by 47% (RR [CI]=0.53[0.38, 0.75], p=0.0004). The patients in the MSCs treatment group realised an average of 117.01m (MD [95% CI]=117.01m [94.87, 139.14], p<0.00001) improvement in 6MWT. MSCs transplantation significantly improved Left Ventricular Ejection Fraction (LVEF) by 5.66 % (MD [95% CI]=5.66 [4.39, 6.92], p<0.00001), decreased Left Ventricular End-Systolic Volume (LVESV) by 14.75 ml (MD [95% CI]=-14.75 [-16.18, - 12.83], p<0.00001) and Left Ventricular End-Diastolic Volume (LVEDV) by 5.78 ml (MD [95% CI]=- 5.78[-12.00, 0.43], p=0.07), in the MSCs group, BNP was decreased by 133.51 pg/ml MD [95% CI]= - 133.51 [-228.17,-38.85], p=0.54, I2= 0.0%) than did in the placebo group.

Conclusion: Our results suggested that mesenchymal stem cells as a regenerative therapeutic approach for heart failure are safe and effective by virtue of their self-renewal potential, vast differentiation capacity and immune modulating properties. Allogenic MSCs have superior therapeutic effects and intracoronary injection is the optimum delivery approach. In the tissue origin, patients who received treatment with umbilical cord MSCs seem more effective than bone marrow MSCs. As to dosage injected, (1-10)*10^8 cells were of better effect.

Keywords: Mesenchymal stem cells, heart failure, systematic review, meta-analysis, end-systolic volume, allogenic.

« Previous
[1]
Muñoz-Cánoves P, Huch M. Definitions for adult stem cells debated. Nature 2018; 563(7731): 328-9.
[http://dx.doi.org/10.1038/d41586-018-07175-6] [PMID: 30378594]
[2]
Heidenreich PA, Trogdon JG, Khavjou OA, et al. American Heart Association Advocacy Coordinating Committee; Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council on Arteriosclerosis; Thrombosis and Vascular Biology; Council on Cardiopulmonary; Critical Care; Perioperative and Resuscitation; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease; Council on Cardiovascular Surgery and Anesthesia, and Interdisciplinary Council on Quality of Care and Outcomes Research. Forecasting the future of cardiovascular disease in the United States: A policy statement from the American Heart Association. Circulation 2011; 123(8): 933-44.
[http://dx.doi.org/10.1161/CIR.0b013e31820a55f5] [PMID: 21262990]
[3]
Lloyd-Jones D, Adams R, Carnethon M, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009; 119(3): e21-e181.
[PMID: 19075105]
[4]
O’Connell JB, Bristow MR. Economic impact of heart failure in the United States: Time for a different approach. J Heart Lung Transplant 1994; 13(4): S107-12.
[PMID: 7947865]
[5]
Croft JB, Giles WH, Pollard RA, Keenan NL, Casper ML, Anda RF. Heart failure survival among older adults in the United States: A poor prognosis for an emerging epidemic in the Medicare population. Arch Intern Med 1999; 159(5): 505-10.
[http://dx.doi.org/10.1001/archinte.159.5.505] [PMID: 10074960]
[6]
Ponikowski P, Voors AA, Anker SD, et al. Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18(8): 891-975.
[http://dx.doi.org/10.1002/ejhf.592] [PMID: 27207191]
[7]
Chen SL, Fang WW, Qian J, et al. Improvement of cardiac function after transplantation of autologous bone marrow mesenchymal stem cells in patients with acute myocardial infarction. Chin Med J (Engl) 2004; 117(10): 1443-8.
[PMID: 15498362]
[8]
Horwitz EM, Le Blanc K, Dominici M, et al. International Society for Cellular Therapy. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy 2005; 7(5): 393-5.
[http://dx.doi.org/10.1080/14653240500319234] [PMID: 16236628]
[9]
Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8(4): 315-7.
[http://dx.doi.org/10.1080/14653240600855905] [PMID: 16923606]
[10]
Golpanian S, Wolf A, Hatzistergos KE, Hare JM. Rebuilding the damaged heart: mesenchymal stem cells, cell-based therapy, and engineered heart tissue. Physiol Rev 2016; 96(3): 1127-68.
[http://dx.doi.org/10.1152/physrev.00019.2015] [PMID: 27335447]
[11]
Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: Their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007; 25(11): 2739-49.
[http://dx.doi.org/10.1634/stemcells.2007-0197] [PMID: 17656645]
[12]
Egusa H, Sonoyama W, Nishimura M, Atsuta I, Akiyama K. Stem cells in dentistry-Part II: Clinical applications. J Prosthodont Res 2012; 56(4): 229-48.
[http://dx.doi.org/10.1016/j.jpor.2012.10.001] [PMID: 23137671]
[13]
Yang B, Qiu Y, Zhou N, et al. Application of stem cells in oral disease therapy: Progresses and perspectives. Front Physiol 2017; 8: 197.
[http://dx.doi.org/10.3389/fphys.2017.00197] [PMID: 28421002]
[14]
Tatullo M, Marrelli M, Paduano F. The regenerative medicine in oral and maxillofacial surgery: The most important innovations in the clinical application of mesenchymal stem cells. Int J Med Sci 2015; 12(1): 72-7.
[http://dx.doi.org/10.7150/ijms.10706] [PMID: 25552921]
[15]
Ballini A, Boccaccio A, Saini R, Van Pham P, Tatullo M. Dental-derived stem cells and their secretome and interactions with bioscaffolds/biomaterials in regenerative medicine: From the in vitro research to translational applications. Stem Cells Int 2017; 201769: 75251.
[http://dx.doi.org/10.1155/2017/6975251] [PMID: 29445404]
[16]
Paduano F, Marrelli M, Palmieri F, Tatullo M. CD146 Expression influences periapical cyst mesenchymal stem cell properties. Stem Cell Rev Rep 2016; 12(5): 592-603.
[http://dx.doi.org/10.1007/s12015-016-9674-4] [PMID: 27406247]
[17]
Di Benedetto A, Posa F, Carbone C, et al. NURR1 Downregulation Favors Osteoblastic Differentiation of MSCs. Stem Cells Int 2017; •••20177617048
[http://dx.doi.org/10.1155/2017/7617048] [PMID: 28769982]
[18]
Cantore S, Crincoli V, Boccaccio A, et al. Recentadvancesin endocrine, metabolic and immune disorders: Mesenchymal stemcells(MSCs)andengineeredscaffolds. Endocr Metab Immune Disord Drug Targets 2018; 18(5): 466-9.
[http://dx.doi.org/10.2174/1871530318666180423102905] [PMID: 29692270]
[19]
Boccaccio A, Uva AE, Fiorentino M, Monno G, Ballini A. and A. Desiate, “Optimal load for bone tissues caffolds with an assigned geometry. Int J Med Sci 2018; 15(1): 16-22.
[http://dx.doi.org/10.7150/ijms.20522] [PMID: 29333083]
[20]
Marrelli M, Codispoti B, Shelton RM, et al. Dental pulp stem cell mechanoresponsiveness: Effects of mechanical stimuli on dental pulp stem cell behavior. Front Physiol 2018; 9: 1685.
[http://dx.doi.org/10.3389/fphys.2018.01685] [PMID: 30534086]
[21]
Tatullo M, Codispoti B, Pacifici A, et al. Potential use of human periapical cyst-mesenchymal stem cells (hpcy-mscs) as a novel stem cell source for regenerative medicine applications. Front Cell Dev Biol 2017; 5: 103.
[http://dx.doi.org/10.3389/fcell.2017.00103] [PMID: 29259970]
[22]
Spagnuolo G, Codispoti B, Marrelli M, Rengo C, Rengo S, Tatullo M. Commitment of oral-derived stem cells in dental and maxillofacial applications. Dent J (Basel) 2018; 6(4): 72.
[http://dx.doi.org/10.3390/dj6040072] [PMID: 30551556]
[23]
Marrazzo P, Paduano F, Palmieri F, Marrelli M, Tatullo M. Highly efficient in vitro reparative behaviour of dental pulp stem cells cultured with standardised platelet lysate supplementation. Stem Cells Int 2016.20167230987
[http://dx.doi.org/10.1155/2016/7230987] [PMID: 27774106]
[24]
Higgins JP, Thompson SG. Cochrane Collaboration: Cochrane handbook for systematic reviews of interventions [EB/OL] http://www. cochranehandbook.org
[25]
Wang JA, Xie XJ, He H, et al. A prospective, randomized, controlled trial of autologous mesenchymal stem cells transplantation for dilated cardiomyopathy. Zhonghua Xin Xue Guan Bing Za Zhi 2006; 34(2): 107-10.
[PMID: 16626573]
[26]
Bartunek J, Behfar A, Dolatabadi D, et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol 2013; 61(23): 2329-38. [J].
[http://dx.doi.org/10.1016/j.jacc.2013.02.071] [PMID: 23583246]
[27]
Heldman AW, DiFede DL, Fishman JE, et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: The TAC-HFT randomized trial. JAMA 2014; 311(1): 62-73.
[http://dx.doi.org/10.1001/jama.2013.282909] [PMID: 24247587]
[28]
Perin EC, Borow KM, Silva GV, et al. A phase II dose-escalation study of allogeneic mesenchymal precursor cells in patients with ischemic or nonischemic heart failure. Circ Res 2015; 117(6): 576-84.
[http://dx.doi.org/10.1161/CIRCRESAHA.115.306332] [PMID: 26148930]
[29]
Mathiasen AB, Qayyum AA, Jørgensen E, et al. Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: A randomized placebo-controlled trial (MSC-HF trial). Eur Heart J 2015; 36(27): 1744-53.
[http://dx.doi.org/10.1093/eurheartj/ehv136] [PMID: 25926562]
[30]
Zhao XF, Xu Y, Zhu ZY, Gao CY, Shi YN. Clinical observation of umbilical cord mesenchymal stem cell treatment of severe systolic heart failure. Genet Mol Res 2015; 14(2): 3010-7.
[http://dx.doi.org/10.4238/2015.April.10.11] [PMID: 25966065]
[31]
Bartolucci J, Verdugo FJ, González PL, et al. Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: A phase 1/2 randomized controlled trial (RIMECARD trial [Randomized clinical trial of intravenous infusion umbilical cord mesenchymal stem cells on cardiopathy]). Circ Res 2017; 121(10): 1192-204. [J].
[http://dx.doi.org/10.1161/CIRCRESAHA.117.310712] [PMID: 28974553]
[32]
Teerlink JR, Metra M, Filippatos GS, et al. CHART Investigators. Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: Results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) study. Eur J Heart Fail 2017; 19(11): 1520-9.
[http://dx.doi.org/10.1002/ejhf.898] [PMID: 28560782]
[33]
Butler J, Epstein SE, Greene SJ, et al. Intravenous allogeneic mesenchymal stem cells for nonischemic cardiomyopathy. Safety and efficacy results of a phase II-A randomized trial. Circ Res 2017; 120(2): 332-40.
[http://dx.doi.org/10.1161/CIRCRESAHA.116.309717] [PMID: 27856497]
[34]
Xiao W, Guo S, Gao C, et al. A randomized comparative study on the efficacy of intracoronary infusion of autologous bone marrow mononuclear cells and mesenchymal stem cells in patients with dilated cardiomyopathy. Int Heart J 2017; 58(2): 238-44.
[http://dx.doi.org/10.1536/ihj.16-328] [PMID: 28190794]
[35]
Kim SH, Cho JH, Lee YH, et al. Improvement in left ventricular function with intracoronary mesenchymal stem cell therapy in a patient with anterior wall ST-segment elevation myocardial infarction. Cardiovasc Drugs Ther 2018; 32(4): 329-38.
[http://dx.doi.org/10.1007/s10557-018-6804-z] [PMID: 29956042]
[36]
Yau TM, Pagani FD, Mancini DM, et al. Cardiothoracic Surgical Trials Network. Intramyocardial injection of mesenchymal precursor cells and successful temporary weaning from left ventricular assist device support in patients with advanced heart failure. JAMA 2019; 321(12): 1176-86.
[http://dx.doi.org/10.1001/jama.2019.2341] [PMID: 30912838]
[37]
Hare JM, DiFede DL, Rieger AC, et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON‐DCM trial. J Am Coll Cardiol 2017; 69(5): 526-37.
[http://dx.doi.org/10.1016/j.jacc.2016.11.009] [PMID: 27856208]
[38]
Karantalis V, Hare JM. Use of mesenchymal stem cells for therapy of cardiac disease. Circ Res 2015; 116(8): 1413-30.
[http://dx.doi.org/10.1161/CIRCRESAHA.116.303614] [PMID: 25858066]
[39]
Hodgkinson CP, Bareja A, Gomez JA, Dzau VJ. Emerging concepts in paracrine mechanisms in regenerative cardiovascular medicine and biology. Circ Res 2016; 118(1): 95-107.
[http://dx.doi.org/10.1161/CIRCRESAHA.115.305373] [PMID: 26837742]
[40]
Golpanian S, Wolf A, Hatzistergos KE, Hare JM. Rebuilding the damaged heart: Mesenchymal stem cells, cell‐based therapy, and engineered heart tissue. Physiol Rev 2016; 96(3): 1127-68.
[http://dx.doi.org/10.1152/physrev.00019.2015] [PMID: 27335447]
[41]
Premer C, Blum A, Bellio MA, et al. Allogeneic mesenchymal stem cells restore endothelial function in heart failure by stimulating endothelial progenitor cells. EBioMedicine 2015; 2(5): 467-75.
[http://dx.doi.org/10.1016/j.ebiom.2015.03.020] [PMID: 26137590]
[42]
Hatzistergos KE, Saur D, Seidler B, et al. Stimulatory effects of mesenchymal stem cells on cKit+ cardiac stem cells are mediated by SDF1/CXCR4 and SCF/cKit signaling pathways. Circ Res 2016; 119(8): 921-30.
[http://dx.doi.org/10.1161/CIRCRESAHA.116.309281] [PMID: 27481956]
[43]
Raggi C, Berardi AC. Mesenchymal stem cells, aging and regenerative medicine. Muscles Ligaments Tendons J 2012; 2(3): 239-42.
[PMID: 23738303]
[44]
Perin EC, Silva GV, Assad JA, et al. Comparison of intracoronary and transendocardial delivery of allogeneic mesenchymal cells in a canine model of acute myocardial infarction. J Mol Cell Cardiol 2008; 44(3): 486-95.
[http://dx.doi.org/10.1016/j.yjmcc.2007.09.012] [PMID: 18061611]
[45]
Rigol M, Solanes N, Farré J, et al. Effects of adipose tissue-derived stem cell therapy after myocardial infarction: Impact of the route of administration. J Card Fail 2010; 16(4): 357-66.
[http://dx.doi.org/10.1016/j.cardfail.2009.12.006] [PMID: 20350704]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy